Alendronic Acid Produces Greater Effects Than Risedronic Acid On Bone Density And Turnover In Postmenopausal Women With Osteoporosis: Results Of Facts1-international

Background: The objective of the study was to evaluate the effects of alendronic acid once weekly relative to risedronic acid once weekly on bone mineral density (BMD), markers of bone turnover and tolerability in the treatment of osteoporosis in postmenopausal women. Methods: This was a randomised, double-masked, double-dummy multicentre international study (75 centres in 27 countries in Europe, the Americas and Asia-Pacific). A total of 1303 women were screened and 936 with low bone density (T-score ≤-2.0 at the spine, hip trochanter, total hip or femoral neck) were randomised; 91% (n = 854) completed the study. Patients were randomised to treatment with either active alendronic acid 70mg weekly (Fosamax®) and placebo identical to risedronic acid weekly or active risedronic acid 35mg weekly (Actonel®) and placebo identical to alendronic acid weekly for 12 months. The primary efficacy endpoint was the percentage change from baseline in hip trochanter BMD at 12 months. Secondary endpoints included the percentage change from baseline in lumbar spine, total hip and femoral neck BMD; biochemical markers of bone turnover (including serum bone-specific alkaline phosphatase [BSAP] and urinary type I collagen N-telopeptides [NTx]); and safety and tolerability as assessed by reporting of adverse experiences. Results: Alendronic acid produced greater increases in BMD than did risedronic acid at 12 months at all sites measured. Mean percentage increases from baseline in hip trochanter BMD at month 12 were 3.56% and 2.71% in the alendronic acid and risedronic acid groups, respectively (treatment difference [95% CI]: 0.83% [0.22, 1.45; p = 0.008]). Mean percentage increases from baseline were greater with alendronic acid than risedronic acid at the lumbar spine, total hip and femoral neck BMD at month 12 (p = 0.002, p < 0.001, p = 0.039, respectively). Increases in BMD with alendronic acid compared with risedronic acid were also significantly greater at 6 months at the trochanter and total hip. There was a greater reduction in bone turnover with alendronic acid compared with risedronic acid: NTx decreased 58% with alendronic acid compared with 47% with risedronic acid at 12 months (p < 0.001); and BSAP decreased 45% with alendronic acid compared with 34% with risedronic acid at 12 months (p < 0.001). Overall tolerability and upper gastrointestinal tolerability were similar for both agents. Conclusions: Alendronic acid once weekly produced greater BMD increases at both hip and spine sites and greater reductions in bone turnover relative to risedronic acid once weekly. Both agents were well tolerated with no significant difference in upper gastrointestinal adverse experiences. Clinicians should consider these results when making treatment decisions for postmenopausal women with osteoporosis. © 2006 Adis Data Information BV. All rights reserved.2626374McClung, M.R., Bisphosphonates in osteoporosis: Recent clinical experience (2000) Exp Opin Pharmacother, 1, pp. 225-238Wasnich, R.D., Miller, P.D., Antifracture efficacy of antiresorptive agents are related to changes in bone density (2000) J Clin Endocrinol Metab, 85, pp. 231-236Hochberg, M.C., Greenspan, S., Wasnich, R.D., Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents (2002) J Clin Endocrinol Metab, 87, pp. 1586-1592Hochberg, M.C., Ross, P.D., Black, D., Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis (1999) Arthritis Rheum, 42, pp. 1246-1254. , Fracture Intervention Trial Research GroupBauer, D.C., Black, D.M., Garnero, P., Change in bone turnover and hip, nonspine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial (2004) J Bone Miner Res, 19, pp. 1250-1258Cummings, S.R., Karpf, D.B., Harris, F., Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs (2002) Am J Med, 112, pp. 281-289Li, Z., Meredith, M.P., Hoseyni, M.S., A method to assess the proportion of treatment effect explained by a surrogate endpoint (2001) Stat Med, 20, pp. 3175-3188Marcus, R., Wong, M., Heath III, H., Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint (2002) Endocr Rev, 23, pp. 16-37Delmas, P.D., Seeman, E., Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy (2004) Bone, 34, pp. 599-604Miller, P.D., Hochberg, M.C., Wehren, L.E., How useful are measures of BMD and bone turnover? (2005) Curr Med Res Opin, 21, pp. 545-553Cummings, S.R., Black, D.M., Thompson, D.E., Alendronate reduces the risk of vertebral fractures in women without preexisting vertebral fractures: Results from the Fracture Intervention Trial (1998) JAMA, 280, pp. 2077-2082Liberman, U.A., Weiss, S.R., Broll, J., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis (1995) N Engl J Med, 333, pp. 1437-1443Garnero, P., Shih, W.J., Gineyts, E., Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment (1994) J Clin Endocrinol Metab, 79, pp. 1693-1700Bone, H.G., Hosking, D., Devogelaer, J.-P., Ten years' experience with alendronate for osteoporosis in postmenopausal women (2004) N Engl J Med, 350, pp. 1189-1199Cranney, A., Wells, G., Willan, A., Meta-analyses of therapies for postmenopausal osteoporosis: II. Meta-analysis of alendronate for the treatment of postmenopausal women (2002) Endocr Rev, 23, pp. 508-516Ḧauselmann, H.J., Rizzoli, R., A comprehensive review of treatments for postmenopausal osteoporosis (2003) Osteoporos Int, 14, pp. 2-12Levis, S., Quandt, S.A., Thompson, D., Alendronate reduces the risk of multiple symptomatic fractures: Results from the Fracture Intervention Trial (2002) J Am Geriatr Soc, 50, pp. 409-415Black, D.M., Thompson, D.E., Bauer, D.C., Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial (2000) J Clin Endocrinol Metab, 85, pp. 4118-4124. , FIT Research GroupPols, H.A.P., Felsenberg, D., Hanley, Multinational, placebo controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study (1999) Osteoporos Int, 9, pp. 461-468Harris, S.T., Watts, N.B., Genant, H.K., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial (1999) JAMA, 282, pp. 1344-1352. , Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupCranney, A., Guyatt, G., Griffith, L., Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analysis of therapies for postmenopausal women (2002) Endocr Rev, 23, pp. 570-577Kanis, J.A., Oden, A., Johnell, O., Uncertain future of trials in osteoporosis (2002) Osteoporos Int, 13, pp. 443-449McAlister, F.A., Laupacis, A., Wells, G.A., Users' guides to the medical literature: XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect (1999) JAMA, 282, pp. 1371-1377Bucher, H.C., Guyatt, G.H., Cook, D.J., Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate endpoints: Evidence-Based Medicine Working Group (1999) JAMA, 282, pp. 771-778Hosking, D., Adami, S., Felsenberg, D., Comparison of change in bone resorption and bone mineral density with once weekly alendronate and daily risedronate (2003) Curr Med Res Opin, 19, pp. 383-394Rosen, C., Hochberg, M., Bonnick, S., Treatment with once-weekly alendronate 70mg compared to once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized, double-blind study (2005) J Bone Miner Res, 20, pp. 141-151Khosla, S., Surrogates for fracture endpoints in clinical trials (2003) J Bone Miner Res, 18, pp. 1146-1149Cummings, S.R., Black, D.M., Nevitt, M.C., Bone density at various sites for prediction of hip fractures (1993) Lancet, 341, pp. 72-75Eastell, R., Barton, I., Hannon, R.A., Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate (2003) J Bone Miner Res, 18, pp. 1051-1056Epstein, S., The roles of BMD, turnover, and other properties in reducing fracture risk during antiresorptive therapy (2005) Mayo Clin Proc, 80, pp. 379-388Watts, N.B., Cooper, C., Lindsay, R., Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk (2004) J Clin Densitom, 7, pp. 255-261Bonnick, S.L., Johnston, C.C., Kleerekoper, M., The importance of precision in bone density measurements (2001) J Clin Densitom, 4, pp. 105-110Chestnut III, C.H., Rosen, C.J., Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture (2001) J Bone Miner Res, 16, pp. 2163-217